Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cytokinetics, Inc.

http://www.cytokinetics.com

Latest From Cytokinetics, Inc.

Ophthalmic Bevacizumab & CRISPR-Based Gene Therapy Among Latest EU Filings

Investigational drugs from Outlook Therapeutics and Vertex/CRISPR could become first-of-their-kind products if they win marketing approval.

Europe Drug Review

India M&As Overtook PE Activity In 2022, Deal Momentum To Continue In 2023

India had a busy deals calendar in 2022, with companies led by Biocon striking large M&A deals while PE activity declined. Scrip pieced together data for infographics on these deals. A multitude of factors is expected to keep the momentum going in 2023

Commercial Scrip Perspectives

In Vivo’s Deals Of The Year: Cast Your Vote!

It is time for In Vivo's 15th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.

Deals Financing

Jasper Data Show Potential Promise For Anti-CD117 Conditioning Agent

Jasper announced data on the first three patients in the trial of briquilimab in sickle cell disease and beta-thalassemia patients, not long after another player, Magenta, announced a setback in its program.

Blood & Coagulation Disorders Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register